Wed, Apr 16, 2014, 7:33 AM EDT - U.S. Markets open in 1 hr 57 mins

Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 243 posts  |  Last Activity: 16 hours ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Mark McKsymick

    by knight.katherine 18 hours ago
    kadaicher1 kadaicher1 16 hours ago Flag

    When you look a little deeper PBT2 did significantly reduce plaque from the baseline. It is just that th placebo made history and reduced plaque by a lesser amount, but by enough to confound the result. If plaque keeps reducing as I expect there will be continuous plaque reduction over 2 tears.

    Sentiment: Strong Buy

  • Reply to

    RSI 1 yr under 3 Not 30 but 3

    by kadaicher1 18 hours ago
    kadaicher1 kadaicher1 17 hours ago Flag

    Just to clarify, HD Ph2 results were quite good, showing a significant gain in the most difficult test in executive function, TMT B. Then is the sub group of earliest stage patients, a stat sig result over several measures. There was also a signal of reduced hippocanpus atrophy seen in a small sample, then replicated in the IMAGINE trial.
    Reach2HD did everything a phase 2 trial needs to do, identifying trends to improve and identifying a stage of the disease where best to target the approval trial.

    Sentiment: Strong Buy

  • Reply to

    RSI 1 yr under 3 Not 30 but 3

    by kadaicher1 18 hours ago
    kadaicher1 kadaicher1 17 hours ago Flag

    Sorry for the typos.

    Sentiment: Strong Buy

  • Reply to

    RSI 1 yr under 3 Not 30 but 3

    by kadaicher1 18 hours ago
    kadaicher1 kadaicher1 17 hours ago Flag

    It is not a pump that the company have advised they are entering a phase 3 for approval in HD. The extension trial is still running in AD and there is still a possibility of good results there, Target engagement signes are there with reduced atrophy and reduced plaque. AD is not nesarly over, and if they can show something in the IMAGINE extension trial, then when ut is approved in HD there will still be an off label demand in AD.
    Your figures are just nothing.

    Sentiment: Strong Buy

  • Reply to

    Alzforum comments from Colin Masters

    by kadaicher1 Apr 13, 2014 12:45 AM
    kadaicher1 kadaicher1 18 hours ago Flag

    Yes this is from one of the giants in AD research and is very usefull info while that troll is trying to make it dissapers. It needs to be visible for a while during the troll attack.

    Sentiment: Strong Buy

  • Reply to

    This will be going after early stage HD

    by kadaicher1 Apr 12, 2014 11:42 AM
    kadaicher1 kadaicher1 18 hours ago Flag

    I think by the end of the year the Parkinson's drug will also be in the clinic. I think it is special with its ability to organize iron in the system, with its added implications for cancer prevention.

    Sentiment: Strong Buy

  • Reply to

    RSI 1 yr under 3 Not 30 but 3

    by kadaicher1 18 hours ago
    kadaicher1 kadaicher1 18 hours ago Flag

    Now if a company was going to go away, OK, but Prana have never had this much chash the whole time I have been invested here, soc they are not going away, the targets are clear, The trial will be fairly rapid.
    This sort of RSI is BS. A low price cannot even cut off funds for a trial, they have it.

    Sentiment: Strong Buy

  • Shorts overplaying their hand again. This is very cheap for a company which has not yet finished their AD trial.
    The extension trial progresses and with some biomarker trends to back up so earlier studies cognition gains could very easily emerge, even from that tiny trial. Remember is is now better powered with all patients on the drug and going against baseline.
    Expect the hipocampus atrophy fron the ex placebo to slow, suggesting disease modification.
    Huntington-s trial demonstrated significant improvements in in the most difficult Trial Making Test B and a much stronger showing in the early stage patients, which was stst sig over the entire Z score.
    Phase 3 for approval in HD is already flagger and they have the resources.
    PBT434 will be ready for the clinic by year end and that has the most spectacular preclinical results of them all, going for the 4B Parkinsons market.

    Sentiment: Strong Buy

  • Reply to

    Alzforum comments from Colin Masters

    by kadaicher1 Apr 13, 2014 12:45 AM
    kadaicher1 kadaicher1 Apr 14, 2014 1:31 PM Flag

    This is the recent study he spoke about
    Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4013-8. doi: 10.1073/pnas.1402228111. Epub 2014 Mar 3.
    Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity.
    Matlack KE1, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S.
    Author information
    Abstract
    Alzheimer's disease (AD) is a common, progressive neurodegenerative disorder without effective disease-modifying therapies. The accumulation of amyloid-β peptide (Aβ) is associated with AD. However, identifying new compounds that antagonize the underlying cellular pathologies caused by Aβ has been hindered by a lack of cellular models amenable to high-throughput chemical screening. To address this gap, we use a robust and scalable yeast model of Aβ toxicity where the Aβ peptide transits through the secretory and endocytic compartments as it does in neurons. The pathogenic Aβ 1-42 peptide forms more oligomers and is more toxic than Aβ 1-40 and genome-wide genetic screens identified genes that are known risk factors for AD. Here, we report an unbiased screen of ∼140,000 compounds for rescue of Aβ toxicity. Of ∼30 hits, several were 8-hydroxyquinolines (8-OHQs). Clioquinol (CQ), an 8-OHQ previously reported to reduce Aβ burden, restore metal homeostasis, and improve cognition in mouse AD models, was also effective and rescued the toxicity of Aβ secreted from glutamatergic neurons in Caenorhabditis elegans. In yeast, CQ dramatically reduced Aβ peptide levels in a copper-dependent manner by increasing degradation, ultimately restoring endocytic function. This mirrored its effects on copper-dependent oligomer formation in vitro, which was also reversed by CQ. This unbiased screen indicates that copper-dependent Aβ oligomer formation contributes to Aβ toxicity within the secretory/endosomal pathways where it can be targeted with selective metal binding compounds.

    Sentiment: Strong Buy

  • I was right and it will be again. This is a very big over reaction considering HD has always been the fastest way to market and nothing has changed except that they are now funded for it..

    Sentiment: Strong Buy

  • Reply to

    Alzforum comments from Colin Masters

    by kadaicher1 Apr 13, 2014 12:45 AM
    kadaicher1 kadaicher1 Apr 14, 2014 8:50 AM Flag

    Still holding a large parcel myself. I never believed it could get this low based on the HD success.

    Sentiment: Strong Buy

  • Reply to

    Alzforum comments from Colin Masters

    by kadaicher1 Apr 13, 2014 12:45 AM
    kadaicher1 kadaicher1 Apr 13, 2014 7:34 PM Flag

    I would prefer they directed resources to starting the HD trial, orphan drug and PBT434. The IMAGINE extension trial data is stiill rolling in. This phase of the AD proof of concept is not over. One year was always a little ambitious considering the tiny changes, if any, in early stage patients.
    Hopefully the extension will show some data that will make pbt2 interesting for off label use by HD approval.

    Sentiment: Strong Buy

  • Reply to

    Alzforum comments from Colin Masters

    by kadaicher1 Apr 13, 2014 12:45 AM
    kadaicher1 kadaicher1 Apr 13, 2014 12:47 AM Flag

    cont
    Lon's further analogy with a Hail Mary pass invites the rebuttal that the effort was more like an Our Father, or even The Credo: “I believe in one principle, the almighty Aβ, cause of all Alzheimer's disease, both clinical and preclinical."

    For those who appreciate that an n=42 PiB study does not portend the doom of this novel therapeutic, it is hoped that there are others who understand that the real test and opportunity for PBT2 in Alzheimer’s disease lies in an appropriately powered trial to explore clinical benefit.

    Sentiment: Strong Buy

  • Colin Masters
    University of Melbourne
    Posted: 11 Apr 2014
    The IMAGINE study conducted by Prana Biotechnology was a small (n=42) exploratory trial supported by a grant from the Alzheimer’s Drug Discovery Foundation to see if the novel 8-OH quinoline (PBT2) would have an effect on Aβ-amyloid burden as reported by PiB-PET neuroimaging over 12 months. Secondary objectives included MRI volumetry, FDG-PET, cognitive change and Aβ-related blood biomarkers. The draft preliminary results indicated a surprising fall in the PiB SUVRs in the placebo group, which obscured any statistical separation from the drug treatment group (which also showed a larger decrease).

    I agree with most of the comments from Lon Schneider, Bruno Pietro Imbimbo, and Susan Landau. I would prefer to reserve judgement on the study until all the data have been verified, analysed and publicly released, particularly the effect of the ApoE4 polymorphism and the changes in blood biomarkers (especially Aβ dimers). It's worth noting that the IMAGINE trial is still ongoing in an open-label extension study that will conclude in early 2015, and that the overall safety data from the IMAGINE trial so far is excellent.

    Further independent support for the use of this class of drug has come from unbiased screens of Aβ-toxicity (Matlack et al., 2014). Indeed the scientific argument for this therapeutic approach has become more compelling with published data for PBT2 demonstrating its reduction of tau protein, upregulation of synaptic plasticity markers, and reduction of Aβ-induced synaptotoxicity (Adlard et al., 2008).
    It is far too premature to abandon this clinical approach of proof-of-concept. As Lon comments, a reasonable development program would have entailed a much larger study, but unfortunately the funds for this are yet to be sourced.

    Sentiment: Strong Buy

  • Market sizes 20B, .7B and 4B

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Apr 12, 2014 12:21 PM Flag

    Da mining, he is possibly a lying maggot who would never pay up in the unlikely event he actually has any serious money.

    Sentiment: Strong Buy

  • Reply to

    Moving back to Buy

    by goutah3006 Apr 11, 2014 10:33 AM
    kadaicher1 kadaicher1 Apr 12, 2014 12:14 PM Flag

    I imagine they are locked in a data review to see how the placebo figure showed a previously never seen plaque reduction.

    Sentiment: Strong Buy

  • Stat sig in TMTB and STAT sig over complete Z score in early stage group. You listen to the high school grads and I will listen to the docs who know OK.

    Sentiment: Strong Buy

  • With a high probability of success from what I saw from the phase2. Stock looks very cheap. Trial will be quick.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Apr 12, 2014 11:38 AM Flag

    Projections I have heard are from $500 to $1b for a successful disease modifying HD drug. That is why a lot of Biotechs and Pharma are going after it. You need to do some research and stop making yourself look thick.

    Sentiment: Strong Buy

PRAN
1.739-0.151(-7.99%)Apr 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NasdaqGSTue, Apr 15, 2014 4:00 PM EDT
Zebra Technologies Corp.
NasdaqGSTue, Apr 15, 2014 4:00 PM EDT